NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, existing in both oxidized (NAD+) and reduced (NADH) forms. The NAD+/NADH ratio is central to cellular energy metabolism — it is the electron carrier that shuttles electrons through the mitochondrial electron transport chain to produce ATP. Beyond energy production, NAD+ is a required substrate for two classes of longevity-associated enzymes: sirtuins (SIRT1–7: NAD+-dependent deacetylases that regulate gene expression, DNA repair, mitochondrial biogenesis, and metabolic adaptation) and PARPs (PARP1/2: poly-ADP-ribose polymerases that repair DNA strand breaks). Both consume NAD+ during their activity — meaning chronic DNA damage (which increases with age) accelerates NAD+ depletion.
The age-related NAD+ decline is real and well-documented. The question is whether supplementing with NAD+ precursors in humans produces the downstream benefits seen in mice at the doses studied, and whether this translates to meaningful longevity outcomes. The mouse data is compelling and consistent; the human data shows NAD+ levels do rise but functional longevity benefits remain to be established in long-duration trials. This is not a reason to dismiss the field — it is context for calibrating expectations.
| Precursor | Pathway | Human evidence | Cost (monthly) | Considerations |
|---|---|---|---|---|
| NMN (nicotinamide mononucleotide) | Direct NMN → NAD+ via NMNAT (most direct route) | Yoshino 2021 (N=25): 25% muscle NAD+ increase; Igarashi 2022 (N=10): NAD+ rise + metabolic benefits in older men; Liao 2021 (N=80): improved muscle strength and walking speed in older adults | $60–120/month at 500mg/day | Most researched precursor; sublingual form may improve absorption; Sinclair protocol; NMN was briefly removed from FDA supplement market as IND drug (2023 ruling reversed in some jurisdictions — check current status); 500mg–1g/day common research doses |
| NR (nicotinamide riboside) | NR → NMN → NAD+ | Elhassan 2019 (N=12): 90% blood NAD+ increase at 1g/day; Dollerup 2018 (N=40, T2D): NAD+ rise confirmed, no significant metabolic improvement vs placebo; Martens 2018 (N=30, older adults): NAD+ rise, no significant blood pressure effect | $40–80/month at 300mg/day | ChromaDex Tru Niagen is the branded studied form; well-tolerated; no flush; Chromadex holds IP; multiple human trials but most show NAD+ rises without dramatic functional benefits at studied doses and durations |
| Niacin (nicotinic acid) | Niacin → NMN → NAD+ (via Preiss-Handler salvage pathway) | Long-standing cardiovascular data (Coronary Drug Project 1975); Pirinen 2020 (N=40, mitochondrial myopathy): significant NAD+ increase + improved mitochondrial function; niacin raises NAD+ reliably at gram doses | $3–5/month at 500–1000mg/day | Prostaglandin-mediated skin flush is the major tolerability issue (hot/red/itchy skin 30–60 min after dosing); flush reduced by taking with food, aspirin 30 min prior, extended-release forms; most cost-effective precursor; used clinically for decades for lipid management |
| Nicotinamide (NAM) | NAM → NMN → NAD+ (salvage) | Studied for T2D and skin health; raises NAD+ but also inhibits SIRT1 at higher doses (nicotinamide is a product inhibitor of sirtuins) | $5–10/month | Paradoxically, high-dose nicotinamide may inhibit the very sirtuins it's meant to activate; lower doses may avoid this; niacinamide form used topically for skin with strong evidence; avoid as oral longevity protocol due to sirtuin inhibition concern |
Charles Brenner (discoverer of the NR → NAD+ pathway) argues that niacin — available for pennies per dose — raises blood and tissue NAD+ at least as effectively as NMN or NR at practical doses, and that charging $80–120/month for NMN is extracting money from people based on preclinical hype. Brenner's critique is scientifically grounded: the Preiss-Handler pathway (niacin → NAD+) is extremely efficient, and niacin's decades-long safety record is unmatched by any novel precursor. Sinclair counters that the tissue distribution and kinetics of NMN differ from niacin, particularly for brain and muscle NAD+ replenishment, and that resveratrol synergizes with NMN via SIRT1 activation in ways niacin cannot replicate. Both men are correct about parts of the picture. The honest summary: all three precursors raise NAD+; the most cost-effective option with the longest safety record is niacin; NMN has the most targeted research for age-related muscle and metabolic decline; the longevity benefit in humans is unproven for all three.
Cancer cells have high NAD+ demands. Rapidly dividing cancer cells upregulate NAD+ biosynthesis and PARP activity; some oncologists have raised theoretical concerns that NAD+ supplementation could accelerate tumor growth in patients with undiagnosed cancer. This concern is based on mechanistic reasoning, not clinical trial data — there are no human trials showing NAD+ precursors cause or accelerate cancer. PARP inhibitors (which lower NAD+ in cancer cells) are approved cancer treatments. Whether NAD+ supplementation is net beneficial or harmful in cancer contexts is unknown. Individuals with active cancer or high cancer risk should discuss NAD+ supplementation with their oncologist before starting.
Budget option (niacin flush form): Nicotinic acid (niacin) 500mg taken with food; may increase to 500mg twice daily over 2–4 weeks as flush tolerance develops. Take 325mg aspirin 30 minutes prior to reduce prostaglandin-mediated flush. Extended-release niacin reduces flush but carries slightly higher liver enzyme elevation risk (use immediate-release and split doses instead). Cost: ~$3–5/month. Most evidence for cardiovascular benefit at these doses.
No-flush option (NR): Nicotinamide riboside (Tru Niagen or equivalent NR supplement) 300–500mg/day. No flush. Multiple human trials confirming NAD+ elevation. Cost: $40–80/month. Best studied no-flush precursor with the most human trial data.
Muscle/metabolic focus (NMN): NMN 250–500mg/day taken in the morning (Yoshino 2021 used 250mg with significant muscle NAD+ rise). Sublingual NMN may improve absorption. Sinclair protocol adds resveratrol 500mg–1g/day (take with fat for absorption — resveratrol is poorly bioavailable without lipid co-administration) and metformin (prescription). Cost: $60–120/month. Most targeted evidence for skeletal muscle NAD+ and insulin sensitivity.
Synergistic stack: The NAD+ precursor of choice + exercise (exercise independently raises NAD+ via AMPK activation of NAMPT, the rate-limiting enzyme in NAD+ biosynthesis) + caloric restriction or intermittent fasting (activates SIRT1 via NAD+/NADH ratio shift) + adequate sleep (NAD+ recycling occurs during sleep). These behavioral interventions raise NAD+ through independent mechanisms and compound with supplementation. Exercise is the most evidence-supported NAD+-boosting intervention in humans.
A 28-day fillable sleep log built around the seven levers that actually move sleep, so you test one per week and see what it did.
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.